NRAS and cholangiocarcinoma: Herein, we reveal that unlike chronic developmental Sox9 deletion, the acute and therapeutic elimination of Sox9 reduces overall cHCC-CCA tumor burden in Akt-YAP1 but not the Akt-NRAS model.